Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
Abnormally activated CDK9 participates in the super-enhancer mediated transcription of short-lived proteins required for cancer cell survival. Targeting CDK9 has shown potent anti-tumor activity in clinical trials among different cancers. However, the study and knowledge on drug resistance to CDK9 i...
Saved in:
Main Authors: | Chen Hu (Author), Lijuan Shen (Author), Fengming Zou (Author), Yun Wu (Author), Beilei Wang (Author), Aoli Wang (Author), Chao Wu (Author), Li Wang (Author), Jing Liu (Author), Wenchao Wang (Author), Qingsong Liu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma
by: Vivian Jiang, et al.
Published: (2024) -
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
by: Zongru Jiang, et al.
Published: (2020) -
PEG-Bottlebrush Stabilizer-Based Worm-like Nanocrystal Micelles with Long-Circulating and Controlled Release for Delivery of a BCR-ABL Inhibitor against Chronic Myeloid Leukemia (CML)
by: Huamin Liang, et al.
Published: (2022) -
Efficient Synthesis and Docking Analysis of Selective CDK9 Inhibitor NVP-2
by: Abdusaid Saidahmatov, et al.
Published: (2021) -
Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia
by: Zhuoying Chen, et al.
Published: (2024)